Asha Nayak-Kapoor, MD

Associate Professor of Medicine Augusta University

  • Augusta GA

Dr. Nayak's clinical and research interests are in GI Malignancies, and her specialties are Medical Hematology / Oncology Hematology.

Contact

Augusta University

View more experts managed by Augusta University

Spotlight

3 min

Questions about colon cancer? Our experts are here to help with your coverage

Every year, National Colorectal (colon) Cancer Awareness Month is observed during the month of March in an effort to raise awareness of the importance for colon cancer screenings. The recognition offers health care providers the opportunity to educate the general public about a disease that can be preventable, but can sometimes be seen as difficult for patients to discuss with their doctors. In the spirit of education, one of Augusta University’s experts has provided some insight into the subject of colon cancer. Dr. Asha Nayak-Kapoor is an associate professor of medicine in the Division of Hematology/Oncology in the Department of Medicine at the Medical College of Georgia at Augusta University. Nayak is certified by the American Board of Internal Medicine in Hematology and Oncology Specialties. Q: What are the primary risk factors for colon cancer? “Risk factors for colon cancer include: being overweight or obese, not being physically active, certain types of diets, smoking, alcohol use, being older, a personal history of colorectal polyps or colorectal cancer, a personal history of inflammatory bowel disease, a family history of colorectal cancer or adenomatous polyps, having an inherited syndrome. Common symptoms of colorectal cancer include: bloody stool or rectal bleeding, an ongoing change in bowel habits (diarrhea, constipation, chance in stool consistency), abdominal pain or cramping, gas or persistent abdominal discomfort, you feel like your bowels are not voiding completely, weakness, fatigue, or unexplained weight loss.” Q: How can a person protect themselves from the risks of colon cancer? “Colon cancer is largely preventable if patients undergo screening tests, like a surveillance colonoscopy starting at 45 years or earlier depending on family history. Many lifestyle-related factors have been linked to colorectal cancer. In fact, the links between diet, weight, and exercise and colorectal cancer risk are some of the strongest for any type of cancer.  Getting to and staying at a healthy weight may help lower your risk. A diet that's high in red meats (such as beef, pork, lamb, or liver) and processed meats (like hot dogs and some luncheon meats) raises your colorectal cancer risk. Cooking meats at very high temperatures (frying, broiling, or grilling) creates chemicals that might raise your cancer risk. It’s not clear how much this might increase your colorectal cancer risk. Stop smoking. It is best not to drink alcohol. People with a history of colorectal cancer in a first-degree relative (parent, sibling, or child) are at increased risk. The risk is even higher if that relative was diagnosed with cancer when they were younger than 50, or if more than one first-degree relative is affected.” Q: It sometimes seems that colon cancer prevention is aimed more towards men compared to women, but cancer.org lists the risks at 1 in 23 (4.3%) for men and 1 in 25 (4.0%) for women. Is there a reason why perhaps a stigma about colon cancer affecting men more has been created? “According to focus group studies, it can be seen as a taboo topic that is uncomfortable to discuss, and it is not discussed as openly in public as prostate and breast cancer screenings. It can seem embarrassing or humiliating, and can be seen as distasteful dealing with prolonged bowel preparation.” Nayak is a member of several committees, including Onyx and Bayer Speaker Bureau for Nexavar, MCG Cancer Center Molecular Oncology Programme, and MCG Cancer Center Gastrointestinal Tumor Board Committee. If you are a journalist looking to know more about colorectal cancer and would like to speak with an expert for your stories, then let us help. Nayak is available to speak with media about this important subject. Simply click on her icon now to arrange an interview today.

Asha Nayak-Kapoor, MD

Multimedia

Social

Biography

Dr. Nayak graduated with a medical degree in 1982 from the Maulana Azad Medical College Delhi University, followed by Internal Medicine Residency at Coney Island Hospital, SUNY, Brooklyn NY. In 1999, Dr. Nayak was awarded the Hematology Fellowship at Coney Island Hospital, SUNY Brooklyn, NY and the Oncology Fellowship with Augusta University in 2002. Currently Dr. Nayak is an Assistant Professor of Medicine, Department of Hematology / Oncology Department, Augusta University. Dr. Nayak is certified by the American Board of Internal Medicine in Hematology and Oncology Specialties.

Dr. Nayak is currently a member of several committees, including Onyx and Bayer Speaker Bureau for Nexavar, MCG Cancer Center Molecular Oncology Programme, and MCG Cancer Center Gastrointestinal Tumor Board Committee.

Abstracts that Dr. Nayak has participated: Incidence of Red Cell auto-antibodies in Hepatitis C Patients; An Unusual Case of Large Cell Lymphoma in Patients with AIDS.; and Role of Radiochemotherapy in Advanced Biliary Cancers. Publications for Dr. Nayak include: Hepatic Failure caused by Plasma Cell Infiltration in Multiple Myeloma, and Plasmablastic Lymphoma with Small Lymphocytic Lymphoma: Clinicopathologic Features, and Review of the Literature.

Areas of Expertise

Medical hematology/oncology
GI Malignancies
Internal Medicine
Cancer

Affiliations

  • Onyx and Bayer Speaker Bureau for Nexavar : Member
  • MCG Cancer Center Molecular Oncology Programme : Member
  • MCG Cancer Center Gastrointestinal Tumor Board Committee : Member

Media Appearances

Second Opinion Gives Cancer Patient a New Lease on Life!!

Medisense Health  online

2019-11-08

Edwards began receiving treatment at the Georgia Cancer Center in July and was placed under the care of Dr. Asha Nayak-Kapoor, associate professor in the Division of Hematology and Oncology, and Dr. Stephen Ramey, assistant professor in the Department of Radiation Oncology in the Medical College of Georgia.

View More

Articles

Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors

Clinical Cancer Research

The aim of the study was to determine safety, antitumor activity, and pharmacodynamic profile of mogamulizumab, an anti-CCR4 monoclonal antibody targeting effector regulatory T cells (Treg) in combination with the checkpoint inhibitor nivolumab in patients with locally advanced or metastatic solid tumors.

View more

Restoring FAS Expression via Lipid-Encapsulated FAS DNA Nanoparticle Delivery Is Sufficient to Suppress Colon Tumor Growth In Vivo

Cancers

A key feature of human colorectal tumor is loss of FAS expression. FAS is the death receptor for FASL of activated T cells. Loss of FAS expression therefore may promote tumor cell immune escape. We aimed at determining whether restoring FAS expression is sufficient to suppress colorectal tumor growth.

View more

Autocrine IL6-Mediated Activation of the STAT3–DNMT Axis Silences the TNFα–RIP1 Necroptosis Pathway to Sustain Survival and Accumulation of Myeloid-Derived Suppressor Cells

Cancer Research

Although accumulation of myeloid-derived suppressor cells (MDSC) is a hallmark of cancer, the underlying mechanism of this accumulation within the tumor microenvironment remains incompletely understood. We report here that TNFα–RIP1–mediated necroptosis regulates accumulation of MDSCs.

View more